,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078hstUAA'}, 'Id': 'a0P2P0000078hstUAA', 'Event_Date__c': '2020-05-22', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BpdkQAC'}, 'change': None}]",May 2020,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2020', 'fs': 'Oct 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078hsuUAA'}, 'Id': 'a0P2P0000078hsuUAA', 'Event_Date__c': '2020-10-13', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2020', 'Status_History__c': 'a132P000000CFjsQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 19 February 2021', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 19 February 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078hsvUAA'}, 'Id': 'a0P2P0000078hsvUAA', 'Event_Date__c': '2021-02-02', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 19 February 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2021', 'Status_History__c': 'a132P000000Cq2hQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that rivaroxaban for the prevention of major cardiovascular events in patients with peripheral artery disease be listed with a low priority subject to the following Special Authority criteria: </p><p style=""text-align: justify;""><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">INITIAL APPLICATION\xa0</b></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">All of the following: </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient\xa0has peripheral artery\xa0disease and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Previous peripheral artery or carotid revascularisation intervention; or\xa0</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Asymptomatic stenosis\xa0</span><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">&gt;</u><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa050% of the carotid artery diagnosed by angiography or non -invasive imaging; and </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient\xa0must be prescribed rivaroxaban 2.5mg twice daily in combination with\xa0100mg\xa0aspirin\xa0daily;\xa0and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient must not be in the period immediately following\xa0revascularisation when intensified antiplatelet therapy is indicated; and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient must not be on Dual Anti Platelet therapy </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">RENEWAL:\xa0</b></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">The treatment remains appropriate and the patient is benefiting from treatment.\xa0</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on: </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>robust evidence of benefit from the pivotal trial (which was large and well designed) for this patient group, especially for stroke reduction; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high health need for this patient group; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the risk of bleeding being present, although noting that this was mild and manageable, </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>significant uncertainty regarding the patient numbers that would be eligible for rivaroxaban; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the need to fund a reversal agent if rivaroxaban were to be funded for this patient group; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>concern regarding the appropriate dosing for patients in the New Zealand context, compared to the trial population, based on body weight. </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the Māori and Pacific population in New Zealand having a higher absolute risk of MACE due to the presence of comorbidities such as obesity. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that advice be sought from the Cardiovascular Subcommittee regarding New Zealand patients who are considered to be at high risk of major cardiovascular events due to peripheral/coronary artery disease, to define a high-risk population group, and to suggest suitable Special Authority criteria for that patient population.\xa0\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that rivaroxaban for the prevention of major cardiovascular events in patients with peripheral artery disease be listed with a low priority subject to the following Special Authority criteria: </p><p style=""text-align: justify;""><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">INITIAL APPLICATION\xa0</b></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">All of the following: </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient\xa0has peripheral artery\xa0disease and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Previous peripheral artery or carotid revascularisation intervention; or\xa0</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Asymptomatic stenosis\xa0</span><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">&gt;</u><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa050% of the carotid artery diagnosed by angiography or non -invasive imaging; and </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient\xa0must be prescribed rivaroxaban 2.5mg twice daily in combination with\xa0100mg\xa0aspirin\xa0daily;\xa0and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient must not be in the period immediately following\xa0revascularisation when intensified antiplatelet therapy is indicated; and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient must not be on Dual Anti Platelet therapy </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">RENEWAL:\xa0</b></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">The treatment remains appropriate and the patient is benefiting from treatment.\xa0</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on: </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>robust evidence of benefit from the pivotal trial (which was large and well designed) for this patient group, especially for stroke reduction; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high health need for this patient group; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the risk of bleeding being present, although noting that this was mild and manageable, </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>significant uncertainty regarding the patient numbers that would be eligible for rivaroxaban; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the need to fund a reversal agent if rivaroxaban were to be funded for this patient group; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>concern regarding the appropriate dosing for patients in the New Zealand context, compared to the trial population, based on body weight. </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the Māori and Pacific population in New Zealand having a higher absolute risk of MACE due to the presence of comorbidities such as obesity. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that advice be sought from the Cardiovascular Subcommittee regarding New Zealand patients who are considered to be at high risk of major cardiovascular events due to peripheral/coronary artery disease, to define a high-risk population group, and to suggest suitable Special Authority criteria for that patient population.\xa0\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an application from Bayer for the use of rivaroxaban (Xarelto) for the first-line treatment of peripheral artery disease (PAD) with or without coronary artery disease (CAD). The Committee noted that rivaroxaban is currently open listed on the Pharmaceutical Schedule, but that there has been no previous review or consideration for the 2.5 mg formulation, or for the requested indication. The Committee also noted that rivaroxaban (2.5 mg) is Medsafe registered for the requested indication. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD and CAD are clinical presentations of atherosclerosis, which is a progressive condition affecting the large and medium-sized arteries. PAD and CAD develop in different vascular beds but can frequently coexist in patients with multi-vessel disease. The Committee also noted that the main risk factors for atherosclerosis include lack of physical activity, smoking, unhealthy diet, age, and a family history of heart disease. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD is caused by atherosclerosis of the arteries and mainly affects the lower extremities and sometimes the carotid arteries, and that PAD can include asymptomatic and symptomatic disease, the latter including intermittent claudication, chronic limb ischemia, and acute limb ischemia, which can lead to gangrene and amputation. The Committee noted that the unstable plaques in PAD can rupture and trigger acute atherothrombotic events because of embolus formation, such as myocardial infarction, stroke, cardiovascular death, and acute limb ischemia. The Committee noted that PAD is broadly defined as a progressive stenosis or occlusion of any of the arteries except the coronary and intracranial arteries, and that patients with PAD are more than 6 times more likely to have a heart attack or stroke, and 13 times more likely to have lower limb amputation. The Committee also noted that an estimated 50% of people with PAD in New Zealand are underdiagnosed, and undertreated, and that a significant proportion of patients are diagnosed late. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CAD is caused by atherosclerosis of the coronary arteries, which leads to a restriction of blood flow to the heart, and can be categorised into acute coronary syndrome (refers to a range of conditions associated with a sudden, reduce blood flow to the heart including unstable angina and acute myocardial infarction) or chronic CAD (including patients with stable angina and patients who have survived acute limb ischemia and have ‘restabilised’ although patients remain at risk of recurrent major adverse cardiovascular events (MACE), which includes myocardial infarction, stroke and cardiovascular death).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, in New Zealand, men experience PAD at a rate of 491 per 100,000, compared to 347 per 100,000 for women (<a href=""https://thehub.swa.govt.nz/resources/cardiovascular-disease-in-new-zealand-strategic-overview/"" target=""_blank"">Social Wellbeing Agency, 2013</a>). The Committee also noted that Māori experience PAD at a rate of 269 per 100,000 compared to the non-Māori population’s rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from total cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of coronary disease. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported. The Committee considered that there is an increased carer and financial burden on the families of patients with complications from PAD/CAD and MACE, especially in cases like stroke where patients may not be able to work or perform day to day tasks. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant had defined two patient groups in its application: the group of patients in the stable phase of PAD, and the subgroup with diagnoses of PAD and CAD (concurrent). The Committee considered that the PAD and CAD subgroup, should not be considered as a discrete group because patients are unlikely to have peripheral disease without coronary arteries also being affected. The Committee considered that the CAD subgroup would be reasonably representative of the combined PAD and CAD subgroups as both groups would present with CAD. Therefore, patients with CAD would be a surrogate of the PAD and CAD patient group intended by the supplier. The Committee considered that the Cardiovascular Subcommittee would be best placed to define a patient group at higher risk of MACE.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the phase III randomised controlled trial, COMPASS (<a href=""https://pubmed.ncbi.nlm.nih.gov/28844192/"" target=""_blank"">Eikelboom et al. N Engl J Med. 2017;377:1319-30</a>), in which adult patients with stable cardiovascular disease (PAD and/or CAD) were randomised to receive either rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily (n=9152), rivaroxaban 5 mg alone twice daily (n=9117), or aspirin 100 mg alone once daily (n=9126) for a mean duration of 23 months. The Committee noted that approximately 90% of patients had CAD, while 20% had PAD. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that rivaroxaban in combination with aspirin had a lower incidence of MACE when compared to aspirin alone (379 patients vs 496, respectively; HR=0.76; 95% CI 0.66 to 0.86; P&lt;0.001), especially in the case of stroke (HR=0.58; 95% CI 0.44 to 0.76; p&lt;0.001) but did not have a statistically significant impact on the incidence of myocardial infarction (HR=0.86; 95% CI 0.70 to 1.05; p=0.145). The Committee also noted that all-cause mortality was lower in the rivaroxaban with aspirin treatment group compared to with aspirin alone (HR=0.82; 95% CI 0.71 to 0.96; p&lt;0.001), which included a significant difference in cardiovascular mortality (HR=0.78; 95% CI 0.64 to 0.96; p=0.02). </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a COMPASS follow-on study investigating the effects of rivaroxaban on major bleeding events, and noted that there was an increased incidence in adverse events associated with bleeding in the rivaroxaban in combination with aspirin treatment arm compared to the aspirin alone group, but noted that the incidence of fatality from bleeding was not significantly different between the two groups (<a href=""https://pubmed.ncbi.nlm.nih.gov/31537259/"" target=""_blank"">Eikelboom et al. J Am Coll Cardiol. 2019;74:1519-28</a>). </p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the pivotal trial (COMPASS) included a heterogeneous population, and that subsequent subgroup analyses had been published to investigate which population groups derive the most benefit. The Committee noted the COMPASS follow-on study was conducted to identify subsets of patients in COMPASS at higher risk of recurrent vascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>). The Committee noted that patients were stratified by risk using REACH (REduction of Atherothrombosis for Continued Health) atherothrombosis risk score and CART (Classification and Regression Tree) analysis, which reported that high-risk patients using the REACH score were those with two or more vascular beds affected, history of heart failure, or renal insufﬁciency, and by CART analysis were those with ≥2 vascular beds affected, history of heart failure, or diabetes. The Committee noted that for patients with multi-vessel disease i.e. PAD with CAD, the absolute risk reduction for cardiovascular events was 6.02% (HR=0.64; 95% CI 0.51 to 0.81) versus 1.36% (HR=0.80; 95% CI 0.68 to 0.93) for patients with one vascular bed affected. The Committee noted that PAD in the lower limbs presents differently to PAD affecting the carotid arteries, and that PAD affecting lower limbs was poorly represented in this study.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following studies in relation to the use of rivaroxaban 2.5 mg in combination with aspirin for the prevention on MACE in PAD and CAD patients: </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29132879/"" target=""_blank"">Connolly et al. Lancet. 2018;391:205-218</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31054846/"" target=""_blank"">Moayyedi et al. Gastroenterology. 2019;157:403-412.e5.</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29540326/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2018;71:2306-2315</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31072566/"" target=""_blank"">Fox et al. J Am Coll Cadriol. 2019;73:2243-2250</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31163978/"" target=""_blank"">Branch et al. Circulation. 2019;140:529-537</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30654882/"" target=""_blank"">Lamy et al. J Am Coll Cardiol. 2019;73:121-130</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30667279/"" target=""_blank"">Sharma et al. Circulation. 2019;139:1134-1145</a></p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the evidence to be of moderate strength and high quality. The Committee noted that there was no relevant quality of life data from the COMPASS trial available. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the baseline characteristics for the participants in the COMPASS trial had an average age of 68 years, and average BMI of 28, approximately 21% reported tobacco use, 75% had hypertension, and 37.5% had diabetes. The Committee considered that this may not accurately reflect the New Zealand PAD population, specifically the Māori and Pacific PAD populations, as these population groups have disproportionately higher rates of obesity, smoking, and diabetes, risk factor characteristics that were not represented in the COMPASS trial. The Committee considered that the twice daily 2.5 mg dosing schedule from the COMPASS trial may not be as beneficial or effective in a patient population which has a higher average weight, and that patients with a higher BMI may have the same risk of bleeding events before any additional benefit is seen and considered that the Cardiovascular Subcommittee would be best placed to give advice on appropriate dosing for the New Zealand population. The Committee also considered that restricting access to rivaroxaban based on an ankle-brachial index (ABI) &lt; 0.90 would likely restrict diabetic patients who often have an ABI over 1, and that this was not clinically appropriate as restriction criteria. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that although the COMPASS trial duration was 23 months, patients who responded to treatment would likely remain on treatment for life. The Committee noted that the COMPASS trial excluded patients who were at a high risk of major bleeding events and considered that this may mean that bleeding events will occur more frequently in the patient population proposed, where the average risk of major bleeding with likely be higher. The Committee considered, however, that clinicians are experienced with bleeding events of this nature and that these events are manageable. The Committee also noted that the COMPASS trial reported a decrease in bleeding events over time, especially after the first year, noting that those who experience bleeds are likely to cease treatment. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, if rivaroxaban were to be funded for this indication, a reversal agent, such as coagulation factor and exanet alfa, would also have to be funded if needed due to life-threatening or uncontrolled bleeding caused by anticoagulation treatment. The Committee noted that rivaroxaban treatment, would be managed in both primary and secondary care settings and that the frequency of routine monitoring of this patient group with blood tests would not be affected. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the eligible population in New Zealand is likely to be greater than 20,000 patients, due to undertreatment and underdiagnosis of PAD and CAD in the New Zealand population. The Committee considered that the eligible patient population based on the inclusion criteria from the COMPASS trial could be up to 50,000 and that the uptake would be rapid. The Committee considered that, due to potentially large patient numbers, it may be more effective to restrict the patient population to patients classified as being at a high risk of MACE, as this population group also showed an increased benefit from treatment compared with patients with only one vascular bed affected. The Committee considered that considerations regarding patient numbers, uptake rates, and target patient groups should be confirmed by the Cardiovascular Subcommittee. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that advice should be sought from the Cardiovascular Subcommittee regarding appropriate classification of ‘high-risk’ patients, appropriate Special Authority access criteria for that population, numbers of eligible patients, an estimated rate of uptake, and the possible risk of slippage beyond the defined Special Authority group.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an application from Bayer for the use of rivaroxaban (Xarelto) for the first-line treatment of peripheral artery disease (PAD) with or without coronary artery disease (CAD). The Committee noted that rivaroxaban is currently open listed on the Pharmaceutical Schedule, but that there has been no previous review or consideration for the 2.5 mg formulation, or for the requested indication. The Committee also noted that rivaroxaban (2.5 mg) is Medsafe registered for the requested indication. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD and CAD are clinical presentations of atherosclerosis, which is a progressive condition affecting the large and medium-sized arteries. PAD and CAD develop in different vascular beds but can frequently coexist in patients with multi-vessel disease. The Committee also noted that the main risk factors for atherosclerosis include lack of physical activity, smoking, unhealthy diet, age, and a family history of heart disease. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD is caused by atherosclerosis of the arteries and mainly affects the lower extremities and sometimes the carotid arteries, and that PAD can include asymptomatic and symptomatic disease, the latter including intermittent claudication, chronic limb ischemia, and acute limb ischemia, which can lead to gangrene and amputation. The Committee noted that the unstable plaques in PAD can rupture and trigger acute atherothrombotic events because of embolus formation, such as myocardial infarction, stroke, cardiovascular death, and acute limb ischemia. The Committee noted that PAD is broadly defined as a progressive stenosis or occlusion of any of the arteries except the coronary and intracranial arteries, and that patients with PAD are more than 6 times more likely to have a heart attack or stroke, and 13 times more likely to have lower limb amputation. The Committee also noted that an estimated 50% of people with PAD in New Zealand are underdiagnosed, and undertreated, and that a significant proportion of patients are diagnosed late. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CAD is caused by atherosclerosis of the coronary arteries, which leads to a restriction of blood flow to the heart, and can be categorised into acute coronary syndrome (refers to a range of conditions associated with a sudden, reduce blood flow to the heart including unstable angina and acute myocardial infarction) or chronic CAD (including patients with stable angina and patients who have survived acute limb ischemia and have ‘restabilised’ although patients remain at risk of recurrent major adverse cardiovascular events (MACE), which includes myocardial infarction, stroke and cardiovascular death).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, in New Zealand, men experience PAD at a rate of 491 per 100,000, compared to 347 per 100,000 for women (<a href=""https://thehub.swa.govt.nz/resources/cardiovascular-disease-in-new-zealand-strategic-overview/"" target=""_blank"">Social Wellbeing Agency, 2013</a>). The Committee also noted that Māori experience PAD at a rate of 269 per 100,000 compared to the non-Māori population’s rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from total cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of coronary disease. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported. The Committee considered that there is an increased carer and financial burden on the families of patients with complications from PAD/CAD and MACE, especially in cases like stroke where patients may not be able to work or perform day to day tasks. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant had defined two patient groups in its application: the group of patients in the stable phase of PAD, and the subgroup with diagnoses of PAD and CAD (concurrent). The Committee considered that the PAD and CAD subgroup, should not be considered as a discrete group because patients are unlikely to have peripheral disease without coronary arteries also being affected. The Committee considered that the CAD subgroup would be reasonably representative of the combined PAD and CAD subgroups as both groups would present with CAD. Therefore, patients with CAD would be a surrogate of the PAD and CAD patient group intended by the supplier. The Committee considered that the Cardiovascular Subcommittee would be best placed to define a patient group at higher risk of MACE.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the phase III randomised controlled trial, COMPASS (<a href=""https://pubmed.ncbi.nlm.nih.gov/28844192/"" target=""_blank"">Eikelboom et al. N Engl J Med. 2017;377:1319-30</a>), in which adult patients with stable cardiovascular disease (PAD and/or CAD) were randomised to receive either rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily (n=9152), rivaroxaban 5 mg alone twice daily (n=9117), or aspirin 100 mg alone once daily (n=9126) for a mean duration of 23 months. The Committee noted that approximately 90% of patients had CAD, while 20% had PAD. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that rivaroxaban in combination with aspirin had a lower incidence of MACE when compared to aspirin alone (379 patients vs 496, respectively; HR=0.76; 95% CI 0.66 to 0.86; P&lt;0.001), especially in the case of stroke (HR=0.58; 95% CI 0.44 to 0.76; p&lt;0.001) but did not have a statistically significant impact on the incidence of myocardial infarction (HR=0.86; 95% CI 0.70 to 1.05; p=0.145). The Committee also noted that all-cause mortality was lower in the rivaroxaban with aspirin treatment group compared to with aspirin alone (HR=0.82; 95% CI 0.71 to 0.96; p&lt;0.001), which included a significant difference in cardiovascular mortality (HR=0.78; 95% CI 0.64 to 0.96; p=0.02). </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a COMPASS follow-on study investigating the effects of rivaroxaban on major bleeding events, and noted that there was an increased incidence in adverse events associated with bleeding in the rivaroxaban in combination with aspirin treatment arm compared to the aspirin alone group, but noted that the incidence of fatality from bleeding was not significantly different between the two groups (<a href=""https://pubmed.ncbi.nlm.nih.gov/31537259/"" target=""_blank"">Eikelboom et al. J Am Coll Cardiol. 2019;74:1519-28</a>). </p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the pivotal trial (COMPASS) included a heterogeneous population, and that subsequent subgroup analyses had been published to investigate which population groups derive the most benefit. The Committee noted the COMPASS follow-on study was conducted to identify subsets of patients in COMPASS at higher risk of recurrent vascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>). The Committee noted that patients were stratified by risk using REACH (REduction of Atherothrombosis for Continued Health) atherothrombosis risk score and CART (Classification and Regression Tree) analysis, which reported that high-risk patients using the REACH score were those with two or more vascular beds affected, history of heart failure, or renal insufﬁciency, and by CART analysis were those with ≥2 vascular beds affected, history of heart failure, or diabetes. The Committee noted that for patients with multi-vessel disease i.e. PAD with CAD, the absolute risk reduction for cardiovascular events was 6.02% (HR=0.64; 95% CI 0.51 to 0.81) versus 1.36% (HR=0.80; 95% CI 0.68 to 0.93) for patients with one vascular bed affected. The Committee noted that PAD in the lower limbs presents differently to PAD affecting the carotid arteries, and that PAD affecting lower limbs was poorly represented in this study.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following studies in relation to the use of rivaroxaban 2.5 mg in combination with aspirin for the prevention on MACE in PAD and CAD patients: </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29132879/"" target=""_blank"">Connolly et al. Lancet. 2018;391:205-218</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31054846/"" target=""_blank"">Moayyedi et al. Gastroenterology. 2019;157:403-412.e5.</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29540326/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2018;71:2306-2315</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31072566/"" target=""_blank"">Fox et al. J Am Coll Cadriol. 2019;73:2243-2250</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31163978/"" target=""_blank"">Branch et al. Circulation. 2019;140:529-537</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30654882/"" target=""_blank"">Lamy et al. J Am Coll Cardiol. 2019;73:121-130</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30667279/"" target=""_blank"">Sharma et al. Circulation. 2019;139:1134-1145</a></p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the evidence to be of moderate strength and high quality. The Committee noted that there was no relevant quality of life data from the COMPASS trial available. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the baseline characteristics for the participants in the COMPASS trial had an average age of 68 years, and average BMI of 28, approximately 21% reported tobacco use, 75% had hypertension, and 37.5% had diabetes. The Committee considered that this may not accurately reflect the New Zealand PAD population, specifically the Māori and Pacific PAD populations, as these population groups have disproportionately higher rates of obesity, smoking, and diabetes, risk factor characteristics that were not represented in the COMPASS trial. The Committee considered that the twice daily 2.5 mg dosing schedule from the COMPASS trial may not be as beneficial or effective in a patient population which has a higher average weight, and that patients with a higher BMI may have the same risk of bleeding events before any additional benefit is seen and considered that the Cardiovascular Subcommittee would be best placed to give advice on appropriate dosing for the New Zealand population. The Committee also considered that restricting access to rivaroxaban based on an ankle-brachial index (ABI) &lt; 0.90 would likely restrict diabetic patients who often have an ABI over 1, and that this was not clinically appropriate as restriction criteria. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that although the COMPASS trial duration was 23 months, patients who responded to treatment would likely remain on treatment for life. The Committee noted that the COMPASS trial excluded patients who were at a high risk of major bleeding events and considered that this may mean that bleeding events will occur more frequently in the patient population proposed, where the average risk of major bleeding with likely be higher. The Committee considered, however, that clinicians are experienced with bleeding events of this nature and that these events are manageable. The Committee also noted that the COMPASS trial reported a decrease in bleeding events over time, especially after the first year, noting that those who experience bleeds are likely to cease treatment. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, if rivaroxaban were to be funded for this indication, a reversal agent, such as coagulation factor and exanet alfa, would also have to be funded if needed due to life-threatening or uncontrolled bleeding caused by anticoagulation treatment. The Committee noted that rivaroxaban treatment, would be managed in both primary and secondary care settings and that the frequency of routine monitoring of this patient group with blood tests would not be affected. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the eligible population in New Zealand is likely to be greater than 20,000 patients, due to undertreatment and underdiagnosis of PAD and CAD in the New Zealand population. The Committee considered that the eligible patient population based on the inclusion criteria from the COMPASS trial could be up to 50,000 and that the uptake would be rapid. The Committee considered that, due to potentially large patient numbers, it may be more effective to restrict the patient population to patients classified as being at a high risk of MACE, as this population group also showed an increased benefit from treatment compared with patients with only one vascular bed affected. The Committee considered that considerations regarding patient numbers, uptake rates, and target patient groups should be confirmed by the Cardiovascular Subcommittee. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that advice should be sought from the Cardiovascular Subcommittee regarding appropriate classification of ‘high-risk’ patients, appropriate Special Authority access criteria for that population, numbers of eligible patients, an estimated rate of uptake, and the possible risk of slippage beyond the defined Special Authority group.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for rivaroxaban for the prevention of major cardiovascular events in patients with peripheral with or without coronary artery disease. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for rivaroxaban for the prevention of major cardiovascular events in patients with peripheral with or without coronary artery disease. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2021', 'fs': 'May 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078hswUAA'}, 'Id': 'a0P2P0000078hswUAA', 'Event_Date__c': '2021-05-12', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 19 February 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Low', 'Formatted_Date__c': 'May 2021', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that rivaroxaban for the prevention of major cardiovascular events in patients with peripheral artery disease be listed with a low priority subject to the following Special Authority criteria: </p><p style=""text-align: justify;""><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">INITIAL APPLICATION\xa0</b></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">All of the following: </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient\xa0has peripheral artery\xa0disease and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Previous peripheral artery or carotid revascularisation intervention; or\xa0</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Asymptomatic stenosis\xa0</span><u style=""font-family: Arial, sans-serif; font-size: 9pt;"">&gt;</u><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa050% of the carotid artery diagnosed by angiography or non -invasive imaging; and </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient\xa0must be prescribed rivaroxaban 2.5mg twice daily in combination with\xa0100mg\xa0aspirin\xa0daily;\xa0and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient must not be in the period immediately following\xa0revascularisation when intensified antiplatelet therapy is indicated; and</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Patient must not be on Dual Anti Platelet therapy </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-family: Arial, sans-serif; font-size: 9pt;"">RENEWAL:\xa0</b></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">The treatment remains appropriate and the patient is benefiting from treatment.\xa0</span></p><p style=""text-align: justify;""><span style=""font-family: Arial, sans-serif; font-size: 9pt;"">\xa0</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee made this recommendation based on: </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>robust evidence of benefit from the pivotal trial (which was large and well designed) for this patient group, especially for stroke reduction; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the high health need for this patient group; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the risk of bleeding being present, although noting that this was mild and manageable, </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>significant uncertainty regarding the patient numbers that would be eligible for rivaroxaban; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the need to fund a reversal agent if rivaroxaban were to be funded for this patient group; </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>concern regarding the appropriate dosing for patients in the New Zealand context, compared to the trial population, based on body weight. </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the Māori and Pacific population in New Zealand having a higher absolute risk of MACE due to the presence of comorbidities such as obesity. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that advice be sought from the Cardiovascular Subcommittee regarding New Zealand patients who are considered to be at high risk of major cardiovascular events due to peripheral/coronary artery disease, to define a high-risk population group, and to suggest suitable Special Authority criteria for that patient population.\xa0\xa0</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for rivaroxaban for the prevention of major cardiovascular events in patients with peripheral with or without coronary artery disease. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted an application from Bayer for the use of rivaroxaban (Xarelto) for the first-line treatment of peripheral artery disease (PAD) with or without coronary artery disease (CAD). The Committee noted that rivaroxaban is currently open listed on the Pharmaceutical Schedule, but that there has been no previous review or consideration for the 2.5 mg formulation, or for the requested indication. The Committee also noted that rivaroxaban (2.5 mg) is Medsafe registered for the requested indication. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD and CAD are clinical presentations of atherosclerosis, which is a progressive condition affecting the large and medium-sized arteries. PAD and CAD develop in different vascular beds but can frequently coexist in patients with multi-vessel disease. The Committee also noted that the main risk factors for atherosclerosis include lack of physical activity, smoking, unhealthy diet, age, and a family history of heart disease. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD is caused by atherosclerosis of the arteries and mainly affects the lower extremities and sometimes the carotid arteries, and that PAD can include asymptomatic and symptomatic disease, the latter including intermittent claudication, chronic limb ischemia, and acute limb ischemia, which can lead to gangrene and amputation. The Committee noted that the unstable plaques in PAD can rupture and trigger acute atherothrombotic events because of embolus formation, such as myocardial infarction, stroke, cardiovascular death, and acute limb ischemia. The Committee noted that PAD is broadly defined as a progressive stenosis or occlusion of any of the arteries except the coronary and intracranial arteries, and that patients with PAD are more than 6 times more likely to have a heart attack or stroke, and 13 times more likely to have lower limb amputation. The Committee also noted that an estimated 50% of people with PAD in New Zealand are underdiagnosed, and undertreated, and that a significant proportion of patients are diagnosed late. </p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that CAD is caused by atherosclerosis of the coronary arteries, which leads to a restriction of blood flow to the heart, and can be categorised into acute coronary syndrome (refers to a range of conditions associated with a sudden, reduce blood flow to the heart including unstable angina and acute myocardial infarction) or chronic CAD (including patients with stable angina and patients who have survived acute limb ischemia and have ‘restabilised’ although patients remain at risk of recurrent major adverse cardiovascular events (MACE), which includes myocardial infarction, stroke and cardiovascular death).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, in New Zealand, men experience PAD at a rate of 491 per 100,000, compared to 347 per 100,000 for women (<a href=""https://thehub.swa.govt.nz/resources/cardiovascular-disease-in-new-zealand-strategic-overview/"" target=""_blank"">Social Wellbeing Agency, 2013</a>). The Committee also noted that Māori experience PAD at a rate of 269 per 100,000 compared to the non-Māori population’s rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from total cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of coronary disease. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported. The Committee considered that there is an increased carer and financial burden on the families of patients with complications from PAD/CAD and MACE, especially in cases like stroke where patients may not be able to work or perform day to day tasks. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the applicant had defined two patient groups in its application: the group of patients in the stable phase of PAD, and the subgroup with diagnoses of PAD and CAD (concurrent). The Committee considered that the PAD and CAD subgroup, should not be considered as a discrete group because patients are unlikely to have peripheral disease without coronary arteries also being affected. The Committee considered that the CAD subgroup would be reasonably representative of the combined PAD and CAD subgroups as both groups would present with CAD. Therefore, patients with CAD would be a surrogate of the PAD and CAD patient group intended by the supplier. The Committee considered that the Cardiovascular Subcommittee would be best placed to define a patient group at higher risk of MACE.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the phase III randomised controlled trial, COMPASS (<a href=""https://pubmed.ncbi.nlm.nih.gov/28844192/"" target=""_blank"">Eikelboom et al. N Engl J Med. 2017;377:1319-30</a>), in which adult patients with stable cardiovascular disease (PAD and/or CAD) were randomised to receive either rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily (n=9152), rivaroxaban 5 mg alone twice daily (n=9117), or aspirin 100 mg alone once daily (n=9126) for a mean duration of 23 months. The Committee noted that approximately 90% of patients had CAD, while 20% had PAD. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that rivaroxaban in combination with aspirin had a lower incidence of MACE when compared to aspirin alone (379 patients vs 496, respectively; HR=0.76; 95% CI 0.66 to 0.86; P&lt;0.001), especially in the case of stroke (HR=0.58; 95% CI 0.44 to 0.76; p&lt;0.001) but did not have a statistically significant impact on the incidence of myocardial infarction (HR=0.86; 95% CI 0.70 to 1.05; p=0.145). The Committee also noted that all-cause mortality was lower in the rivaroxaban with aspirin treatment group compared to with aspirin alone (HR=0.82; 95% CI 0.71 to 0.96; p&lt;0.001), which included a significant difference in cardiovascular mortality (HR=0.78; 95% CI 0.64 to 0.96; p=0.02). </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a COMPASS follow-on study investigating the effects of rivaroxaban on major bleeding events, and noted that there was an increased incidence in adverse events associated with bleeding in the rivaroxaban in combination with aspirin treatment arm compared to the aspirin alone group, but noted that the incidence of fatality from bleeding was not significantly different between the two groups (<a href=""https://pubmed.ncbi.nlm.nih.gov/31537259/"" target=""_blank"">Eikelboom et al. J Am Coll Cardiol. 2019;74:1519-28</a>). </p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the pivotal trial (COMPASS) included a heterogeneous population, and that subsequent subgroup analyses had been published to investigate which population groups derive the most benefit. The Committee noted the COMPASS follow-on study was conducted to identify subsets of patients in COMPASS at higher risk of recurrent vascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>). The Committee noted that patients were stratified by risk using REACH (REduction of Atherothrombosis for Continued Health) atherothrombosis risk score and CART (Classification and Regression Tree) analysis, which reported that high-risk patients using the REACH score were those with two or more vascular beds affected, history of heart failure, or renal insufﬁciency, and by CART analysis were those with ≥2 vascular beds affected, history of heart failure, or diabetes. The Committee noted that for patients with multi-vessel disease i.e. PAD with CAD, the absolute risk reduction for cardiovascular events was 6.02% (HR=0.64; 95% CI 0.51 to 0.81) versus 1.36% (HR=0.80; 95% CI 0.68 to 0.93) for patients with one vascular bed affected. The Committee noted that PAD in the lower limbs presents differently to PAD affecting the carotid arteries, and that PAD affecting lower limbs was poorly represented in this study.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also noted the following studies in relation to the use of rivaroxaban 2.5 mg in combination with aspirin for the prevention on MACE in PAD and CAD patients: </p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29132879/"" target=""_blank"">Connolly et al. Lancet. 2018;391:205-218</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31054846/"" target=""_blank"">Moayyedi et al. Gastroenterology. 2019;157:403-412.e5.</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29540326/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2018;71:2306-2315</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31072566/"" target=""_blank"">Fox et al. J Am Coll Cadriol. 2019;73:2243-2250</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31163978/"" target=""_blank"">Branch et al. Circulation. 2019;140:529-537</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30654882/"" target=""_blank"">Lamy et al. J Am Coll Cardiol. 2019;73:121-130</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30667279/"" target=""_blank"">Sharma et al. Circulation. 2019;139:1134-1145</a></p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the evidence to be of moderate strength and high quality. The Committee noted that there was no relevant quality of life data from the COMPASS trial available. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the baseline characteristics for the participants in the COMPASS trial had an average age of 68 years, and average BMI of 28, approximately 21% reported tobacco use, 75% had hypertension, and 37.5% had diabetes. The Committee considered that this may not accurately reflect the New Zealand PAD population, specifically the Māori and Pacific PAD populations, as these population groups have disproportionately higher rates of obesity, smoking, and diabetes, risk factor characteristics that were not represented in the COMPASS trial. The Committee considered that the twice daily 2.5 mg dosing schedule from the COMPASS trial may not be as beneficial or effective in a patient population which has a higher average weight, and that patients with a higher BMI may have the same risk of bleeding events before any additional benefit is seen and considered that the Cardiovascular Subcommittee would be best placed to give advice on appropriate dosing for the New Zealand population. The Committee also considered that restricting access to rivaroxaban based on an ankle-brachial index (ABI) &lt; 0.90 would likely restrict diabetic patients who often have an ABI over 1, and that this was not clinically appropriate as restriction criteria. </p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that although the COMPASS trial duration was 23 months, patients who responded to treatment would likely remain on treatment for life. The Committee noted that the COMPASS trial excluded patients who were at a high risk of major bleeding events and considered that this may mean that bleeding events will occur more frequently in the patient population proposed, where the average risk of major bleeding with likely be higher. The Committee considered, however, that clinicians are experienced with bleeding events of this nature and that these events are manageable. The Committee also noted that the COMPASS trial reported a decrease in bleeding events over time, especially after the first year, noting that those who experience bleeds are likely to cease treatment. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that, if rivaroxaban were to be funded for this indication, a reversal agent, such as coagulation factor and exanet alfa, would also have to be funded if needed due to life-threatening or uncontrolled bleeding caused by anticoagulation treatment. The Committee noted that rivaroxaban treatment, would be managed in both primary and secondary care settings and that the frequency of routine monitoring of this patient group with blood tests would not be affected. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the eligible population in New Zealand is likely to be greater than 20,000 patients, due to undertreatment and underdiagnosis of PAD and CAD in the New Zealand population. The Committee considered that the eligible patient population based on the inclusion criteria from the COMPASS trial could be up to 50,000 and that the uptake would be rapid. The Committee considered that, due to potentially large patient numbers, it may be more effective to restrict the patient population to patients classified as being at a high risk of MACE, as this population group also showed an increased benefit from treatment compared with patients with only one vascular bed affected. The Committee considered that considerations regarding patient numbers, uptake rates, and target patient groups should be confirmed by the Cardiovascular Subcommittee. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that advice should be sought from the Cardiovascular Subcommittee regarding appropriate classification of ‘high-risk’ patients, appropriate Special Authority access criteria for that population, numbers of eligible patients, an estimated rate of uptake, and the possible risk of slippage beyond the defined Special Authority group.\xa0</p>', 'Status_History__c': 'a132P000000Cq2qQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078iOdUAI'}, 'Id': 'a0P2P0000078iOdUAI', 'Event_Date__c': '2022-05-04', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2022', 'Status_History__c': 'a132P000000DjvAQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Cardiovascular Advisory Committee meeting to provide advice on Wednesday 8 June 2022', 'fs': 'Assigned to Cardiovascular Advisory Committee meeting to provide advice on Wednesday 8 June 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078iOeUAI'}, 'Id': 'a0P2P0000078iOeUAI', 'Event_Date__c': '2022-05-05', 'Event_Description__c': 'Assigned to Cardiovascular Advisory Committee meeting to provide advice on Wednesday 8 June 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2022', 'Status_History__c': 'a132P000000DzHNQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that rivaroxaban for the treatment of PAD with or without CAD be listed with a <strong>medium</strong> <strong>priority</strong> within the context of treatment of cardiovascular disease, subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">INITIAL APPLICATION\xa0</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p><span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 8pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patients must have a confirmed diagnosis of peripheral artery disease (PAD) and must have one or more of the following high-risk factors:</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Concomitant coronary artery disease; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Confirmed diagnosis of PAD in two or more vascular beds; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diagnosed heart failure (left ventricular ejection fraction greater than or equal to 30% but less than 50%) ; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diagnosed kidney disease classified by an eGFR 15-60ml/min; or </span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diabetes Mellitus and at least one of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">age 60 years or more; or</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">concomitant microalbuminuria; or</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">Patient is of Māori or Pacific Island descent; and </span></p><p><span style=""font-size: 8pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patient must be prescribed rivaroxaban 2.5 mg twice daily in combination with 100 mg aspirin once daily; and</span></p><p><span style=""font-size: 8pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patient must not be on Dual Anti-Platelet therapy</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">RENEWAL:\xa0</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment.\xa0</span></p><p><strong style=""font-size: 9pt;"">\xa0</strong></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee considered the high health need for the PAD with or without CAD patient population, and the lack of currently funded effective treatment options in making this recommendation.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that rivaroxaban for the treatment of PAD with or without CAD be listed with a <strong>medium</strong> <strong>priority</strong> within the context of treatment of cardiovascular disease, subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">INITIAL APPLICATION\xa0</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p><span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 8pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patients must have a confirmed diagnosis of peripheral artery disease (PAD) and must have one or more of the following high-risk factors:</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Concomitant coronary artery disease; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Confirmed diagnosis of PAD in two or more vascular beds; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diagnosed heart failure (left ventricular ejection fraction greater than or equal to 30% but less than 50%) ; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diagnosed kidney disease classified by an eGFR 15-60ml/min; or </span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diabetes Mellitus and at least one of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">age 60 years or more; or</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">concomitant microalbuminuria; or</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">Patient is of Māori or Pacific Island descent; and </span></p><p><span style=""font-size: 8pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patient must be prescribed rivaroxaban 2.5 mg twice daily in combination with 100 mg aspirin once daily; and</span></p><p><span style=""font-size: 8pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patient must not be on Dual Anti-Platelet therapy</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">RENEWAL:\xa0</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment.\xa0</span></p><p><strong style=""font-size: 9pt;"">\xa0</strong></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee considered the high health need for the PAD with or without CAD patient population, and the lack of currently funded effective treatment options in making this recommendation.</p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em>Māori</em> <em>impact</em></h3><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori experience peripheral artery disease (PAD) at a reported rate of 269 per 100,000 compared to the non-Māori population’s reported rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of arterial disease. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported.</p><p><em>Discussion</em></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a supplier application for the use of rivaroxaban 2.5mg for the first-line treatment PAD with or without coronary artery disease (CAD). The Committee noted that PTAC considered this application in <a href=""https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf"" target=""_blank"">February 2021</a> where it was recommended for funding with a low priority for patients with PAD with or without CAD based on robust evidence of benefit, high health need for the requested population group, manageable bleeding risk with rivaroxaban, the need to fund a reversal agent if rivaroxaban were to be funded for this patient population, concern regarding the appropriate dosing for patients in the New Zealand context, and the Māori and Pacific population in New Zealand having a higher absolute risk of major adverse cardiac events (MACE) due to the presence of comorbidities such as obesity.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC recommended that advice be sought from the Cardiovascular Advisory Committee regarding identification of high-risk population groups, and appropriate Special Authority criteria.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that that PAD and CAD are clinical presentations of atherosclerosis, which is a progressive condition affecting the large and medium-sized arteries. The Committee noted that PAD and CAD develop in different vascular beds but can frequently coexist in patients with multi-vessel disease. The Committee also noted that the main risk factors for atherosclerosis include age, smoking, a family history of heart disease, unhealthy diet, and lack of physical activity. The Committee noted that PAD mainly affects the lower extremities and sometimes the carotid arteries, and can include asymptomatic and symptomatic disease, the latter including intermittent claudication, chronic limb ischemia, and acute limb ischemia, which can lead to gangrene and amputation. The Committee noted that the unstable plaques in atherosclerotic disease can rupture and trigger acute atherothrombotic events because of embolus formation, such as myocardial infarction, stroke, cardiovascular death, and acute limb ischemia.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD is broadly defined as a progressive stenosis or occlusion of any of the arteries except the coronary and intracranial arteries, and that patients with PAD are more than six times more likely to have a heart attack or stroke, and 13 times more likely to have lower limb amputation. The Committee noted that CAD is caused by atherosclerosis of the coronary arteries, which leads to a restriction of blood flow to the heart and can be categorised into acute coronary syndrome or chronic CAD. Acute coronary syndrome refers to a range of conditions associated with a sudden, reduced blood flow to the heart and includes unstable angina and acute myocardial infarction, and chronic CAD includes patients with stable angina and patients who have survived acute coronary syndrome events and have ‘restabilised’, although these patients remain at risk of recurrent major adverse cardiovascular events (MACE, which includes myocardial infarction, stroke and cardiovascular death).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that Māori experience PAD at a reported rate of 269 per 100,000 compared to the non-Māori population’s reported rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of PAD. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported, as Māori patients experience a higher prevalence of CAD and exposure to its associated risk factors. The Committee considered that there is an increased carer and financial burden on the whānau and families of patients with complications from PAD/CAD and MACE, especially in cases like stroke where patients may not be able to work or perform day to day tasks.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that non-surgical treatment for peripheral vascular disease is limited to statins, aspirin, and smoking cessation, and that there is an unmet need for treatment options for this patient population. The Committee noted that for both PAD and CAD patient populations, there remains a high incidence of patients having recurrent events on currently available treatments.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the pivotal phase III COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial which gives the primary evidence for the health benefits of rivaroxaban for the prevention of cardiovascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/29132879/"" target=""_blank"">Connolly et al. Lancet. 2018;391:205-18</a>). The Committee noted that patients with stable CAD and/or PAD (N=27395) were randomised to receive rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily, rivaroxaban 5 mg alone twice daily, or aspirin 100 mg alone once daily. The Committee noted that participants in COMPASS were either 65 years of age or older or were under the age of 65 with documented atherosclerosis in two vascular beds or at least two additional risk factors. The Committee noted that the primary outcomes of COMPASS were composite incidence of cardiovascular related death or myocardial infarction, and that the primary safety outcome was incidence of major bleeding.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in the COMPASS trial, CAD was defined as previous myocardial infarction within the last 20 years, symptoms or history of stable or unstable angina with confirmed multivessel CAD &gt;50% in at least two coronary arteries (or in one coronary territory if at least one other territory has been revascularized), multivessel percutaneous coronary intervention, multivessel coronary artery bypass grafting (CABG). The Committee also noted that PAD was defined as previous peripheral vascular surgery or peripheral angioplasty intervention, previous amputation for arterial vascular disease, history of intermittent claudication and either an ankle-brachial index &lt;0.9 or a significant peripheral artery stenosis ≥50% documented on imaging, or asymptomatic carotid artery stenosis≥50% / previous carotid revascularisation.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the mean body mass index (BMI) of participants in the COMPASS trial was lower than the expected mean BMI of New Zealand patients, and also noted that most patients participating in the trial were already well managed in terms of treatment and secondary prevention. The Committee noted that 90% of participants in the COMPASS trial had CAD, while only 27% had PAD.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that rivaroxaban in combination with aspirin was clinically and statistically superior to aspirin alone in reducing cardiovascular death, stroke, and myocardial infarction (hazard ratio (HR) 0.76; 95% CI 0.66 to 0.86; P&lt;0.001). The Committee also noted that rivaroxaban in combination with aspirin has a significant benefit in terms of stroke incidence compared to aspirin alone (HR 0.58; 95% CI 0.44 to 0.76; P&lt;0.001).</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was a higher incidence of major bleeding events with rivaroxaban in combination with aspirin, compared to aspirin alone (HR 1.70; 95% CI 1.40 to 2.05; P&lt;0.001), but noted that there was no difference between the treatment groups for intracranial bleeding. The Committee noted that the bleeding events were primarily manageable gastrointestinal events. The Committee noted that the net clinical benefit of rivaroxaban in combination with aspirin compared to aspirin alone still favoured the combination treatment regardless of the increase in bleeding events (HR 0.80; 95% CI 0.70 to 0.91; P&lt;0.001).</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a COMPASS sub-study in which the absolute benefit of rivaroxaban in combination with aspirin was demonstrated to be greater in the sub-set of patients with PAD as opposed to CAD alone (<a href=""https://pubmed.ncbi.nlm.nih.gov/29132880/"" target=""_blank"">Anand et al. Lancet. 2018;391:219-29</a>) and was sustained in patients with two or more vascular beds involved (<a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>), those with renal dysfunction (<a href=""https://pubmed.ncbi.nlm.nih.gov/31072566/"" target=""_blank"">Fox et al. J Am Coll Cardiol. 2019;73:2243-50</a>), heart failure (<a href=""https://pubmed.ncbi.nlm.nih.gov/31163978/"" target=""_blank"">Branch et al. Circulation. 2019;140:529-37</a>), those with diabetes mellitus (<a href=""https://pubmed.ncbi.nlm.nih.gov/32223318/"" target=""_blank"">Bhatt et al. Circulation. 2020;141:1841-54</a>), and regardless of BMI (<a href=""https://pubmed.ncbi.nlm.nih.gov/33538248/"" target=""_blank"">Guzik et al. J Am Coll Cardiol. 2021;77:511-25</a>).</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted that an additional study on the safety of proton pump inhibitors was conducted with patients from the COMPASS trial who received pantoprazole 40 mg once daily or placebo to determine if pantoprazole compared with placebo reduces the risk of upper gastrointestinal (GI) bleeding, ulceration, obstruction, or perforation in those participating in the trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a>). The Committee noted that addition of pantoprazole did not affect the occurrence of upper GI events in the rivaroxaban with aspirin arm but did significantly reduce upper GI events in the aspirin alone arm (HR 0.58; 95% CI 0.35 to 0.96).</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the COMPASS trial was well designed, and that the strength and quality of the evidence was high. The Committee considered that, as there are currently limited options for the treatment of PAD, rivaroxaban in combination with aspirin provides clinical benefit in terms of reducing ischaemia and amputation. The Committee considered that there were clinically beneficial endpoints.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the randomised, double-blind, placebo-controlled VOYAGER trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/32222135/"" target=""_blank"">Bonaca et al. N Engl J Med. 2020;382:1994-2004</a>) investigating the effects of rivaroxaban 2.5 mg twice daily in combination with aspirin once daily versus aspirin alone in those with PAD following arterial revascularisation. The Committee noted that the primary outcome was a composite of acute limb ischemia, major amputation, myocardial infarction, ischaemic stroke, and cardiovascular death. The Committee noted that the primary efficacy outcome occurred in 508 patients in the rivaroxaban group and in 584 in the placebo group; the Kaplan-Meier estimates of the incidence at 3 years were 17.3% and 19.9%, respectively (hazard ratio, 0.85, 95% CI, 0.76 to 0.96; P = 0.009). The Committee also noted that major bleeding occurred in 62 patients in the rivaroxaban group and in 44 patients in the placebo group (2.65% and 1.87%; hazard ratio, 1.43; 95% CI, 0.97 to 2.10; P = 0.07).</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the only currently funded therapy for the prevention of PAD and CAD is aspirin alone, and that there have been a number of trials investigating other agents such as aspirin in combination with clopidogrel or ticagrelor. The Committee noted that these other agents have demonstrated limited benefit after one year, and with limited to no mortality benefit (<a href=""https://pubmed.ncbi.nlm.nih.gov/30871353/"" target=""_blank"">Palmerini et al. Circ Cardiovasc Interv. 2019;12:e007541</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/25773268/"" target=""_blank"">Bonaca et al. N Engl J Med. 2015;372:1791-900</a>). The Committee also noted that warfarin has been shown to improve recurrent ischaemia outcomes but increases the risk of bleeding.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there have been various studies published with the aim to identify those at higher risk within the COMPASS trial cohort:</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a>: reported that rivaroxaban reduced cardiovascular event rates independently of the number of established CVD risk factors (poor control of blood pressure, cholesterol, smoking status), with similar relative risk reductions reported across groups of patients with differing numbers of risk factors. The Committee noted that the largest absolute benefit (in terms of &#39;numbers needed to treat&#39;) was reported in patients with the highest number of risk factors.</p><p class=""ql-indent-1"">1.19.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>: a COMPASS follow-on study conducted to identify subsets of patients in the COMPASS trial at higher risk of recurrent vascular events. The Committee noted that patients were stratified by risk using REACH (REduction of Atherothrombosis for Continued Health) atherothrombosis risk score and CART (Classification and Regression Tree) analysis, which reported that high-risk patients using the REACH score were those with two or more vascular beds affected, history of heart failure, or renal insufﬁciency, and by CART analysis were those with ≥2 vascular beds affected, history of heart failure, or diabetes. The Committee noted that for patients with multi-vessel disease, i.e. PAD with CAD, the absolute risk reduction for cardiovascular events was 6.02% (HR=0.64; 95% CI 0.51 to 0.81) versus 1.36% (HR=0.80; 95% CI 0.68 to 0.93) for patients with one vascular bed affected.</p><p class=""ql-indent-1"">1.19.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29132880/"" target=""_blank"">Anand et al. Lancet. 2018;391:219-29</a>: investigated cardiovascular death, myocardial infarction or stroke in participants with PAD; the primary peripheral artery disease outcome was major adverse limb events including major amputation. The Committee noted that the combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (5% vs 7%; HR 0.72; 95% CI 0.57 to 0.90; p=0.0047), and major adverse limb events including major amputation (1% vs 2%; HR 0.54; 95% CI 0.35 to 0.82; p=0.0037).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the COMPASS trial participants were not representative of the New Zealand Māori and Pacific patient population, as it included fewer smokers, fewer participants with chronic kidney disease, generally lower BMI patients, and lower diabetes incidence, and an over-representation of hypertension. The Committee considered, however, that any benefits from rivaroxaban in combination with aspirin would likely result in enhanced benefits for the Māori and Pacific patient population.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that using ankle-brachial index (ABI) as restriction criteria for access to rivaroxaban, if it were to be funded, may not be clinically appropriate, as it is only one component of the definition of PAD and is variably accessible across centres. The Committee also noted that treating those at a higher risk of adverse bleeding events comes down to individual clinical input and is regularly considered when initiating and managing patients on anticoagulant therapy. The Committee considered that there is a minimal need for haemostatic/reversal agents if rivaroxaban were to be funded for the requested indication, as higher doses of rivaroxaban have been funded in New Zealand for some time without the availability of a dedicated reversal agent.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that twice daily dosing is not as suitable as once daily dosing for most patients which may affect adherence to treatment over the long term.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the prevalence of PAD is 0.42%, equating to approximately 21,000 patients (<a href=""https://thehub.swa.govt.nz/resources/cardiovascular-disease-in-new-zealand-strategic-overview/"" target=""_blank"">National Health Committee, 2013</a>). The Committee considered that a restriction of rivaroxaban access based on identification of high-risk groups and a clear definition of underlying conditions, such as in <a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. (2019)</a> would limit patient numbers to those with the highest need.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the PBAC (Australia) guidelines for access to funded rivaroxaban for those with CAD and PAD, considered that the criteria were specific and detailed in their definitions of high-risk patient populations, and noted that ethnicity was included as a part of the Australian access criteria (for those with Aboriginal or Torres Straight Island descent). The Committee considered that this approach would also be appropriate in the New Zealand treatment context.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the patients who would benefit most from treatment with rivaroxaban include those with widespread disease (i.e. those with both PAD and CAD), and that those with the poorest risk control had the highest benefit in the COMPASS trial.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for rivaroxaban 2.5 mg if it were to be funded in New Zealand for the prevention of PAD with or without CAD. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. </span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0P2P0000078iOf&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002ZNDl"" alt=""image.png""></img></p>', 'fs': '<h3><em>Māori</em> <em>impact</em></h3><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori experience peripheral artery disease (PAD) at a reported rate of 269 per 100,000 compared to the non-Māori population’s reported rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of arterial disease. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported.</p><p><em>Discussion</em></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a supplier application for the use of rivaroxaban 2.5mg for the first-line treatment PAD with or without coronary artery disease (CAD). The Committee noted that PTAC considered this application in <a href=""https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf"" target=""_blank"">February 2021</a> where it was recommended for funding with a low priority for patients with PAD with or without CAD based on robust evidence of benefit, high health need for the requested population group, manageable bleeding risk with rivaroxaban, the need to fund a reversal agent if rivaroxaban were to be funded for this patient population, concern regarding the appropriate dosing for patients in the New Zealand context, and the Māori and Pacific population in New Zealand having a higher absolute risk of major adverse cardiac events (MACE) due to the presence of comorbidities such as obesity.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC recommended that advice be sought from the Cardiovascular Advisory Committee regarding identification of high-risk population groups, and appropriate Special Authority criteria.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that that PAD and CAD are clinical presentations of atherosclerosis, which is a progressive condition affecting the large and medium-sized arteries. The Committee noted that PAD and CAD develop in different vascular beds but can frequently coexist in patients with multi-vessel disease. The Committee also noted that the main risk factors for atherosclerosis include age, smoking, a family history of heart disease, unhealthy diet, and lack of physical activity. The Committee noted that PAD mainly affects the lower extremities and sometimes the carotid arteries, and can include asymptomatic and symptomatic disease, the latter including intermittent claudication, chronic limb ischemia, and acute limb ischemia, which can lead to gangrene and amputation. The Committee noted that the unstable plaques in atherosclerotic disease can rupture and trigger acute atherothrombotic events because of embolus formation, such as myocardial infarction, stroke, cardiovascular death, and acute limb ischemia.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD is broadly defined as a progressive stenosis or occlusion of any of the arteries except the coronary and intracranial arteries, and that patients with PAD are more than six times more likely to have a heart attack or stroke, and 13 times more likely to have lower limb amputation. The Committee noted that CAD is caused by atherosclerosis of the coronary arteries, which leads to a restriction of blood flow to the heart and can be categorised into acute coronary syndrome or chronic CAD. Acute coronary syndrome refers to a range of conditions associated with a sudden, reduced blood flow to the heart and includes unstable angina and acute myocardial infarction, and chronic CAD includes patients with stable angina and patients who have survived acute coronary syndrome events and have ‘restabilised’, although these patients remain at risk of recurrent major adverse cardiovascular events (MACE, which includes myocardial infarction, stroke and cardiovascular death).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that Māori experience PAD at a reported rate of 269 per 100,000 compared to the non-Māori population’s reported rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of PAD. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported, as Māori patients experience a higher prevalence of CAD and exposure to its associated risk factors. The Committee considered that there is an increased carer and financial burden on the whānau and families of patients with complications from PAD/CAD and MACE, especially in cases like stroke where patients may not be able to work or perform day to day tasks.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that non-surgical treatment for peripheral vascular disease is limited to statins, aspirin, and smoking cessation, and that there is an unmet need for treatment options for this patient population. The Committee noted that for both PAD and CAD patient populations, there remains a high incidence of patients having recurrent events on currently available treatments.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the pivotal phase III COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial which gives the primary evidence for the health benefits of rivaroxaban for the prevention of cardiovascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/29132879/"" target=""_blank"">Connolly et al. Lancet. 2018;391:205-18</a>). The Committee noted that patients with stable CAD and/or PAD (N=27395) were randomised to receive rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily, rivaroxaban 5 mg alone twice daily, or aspirin 100 mg alone once daily. The Committee noted that participants in COMPASS were either 65 years of age or older or were under the age of 65 with documented atherosclerosis in two vascular beds or at least two additional risk factors. The Committee noted that the primary outcomes of COMPASS were composite incidence of cardiovascular related death or myocardial infarction, and that the primary safety outcome was incidence of major bleeding.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in the COMPASS trial, CAD was defined as previous myocardial infarction within the last 20 years, symptoms or history of stable or unstable angina with confirmed multivessel CAD &gt;50% in at least two coronary arteries (or in one coronary territory if at least one other territory has been revascularized), multivessel percutaneous coronary intervention, multivessel coronary artery bypass grafting (CABG). The Committee also noted that PAD was defined as previous peripheral vascular surgery or peripheral angioplasty intervention, previous amputation for arterial vascular disease, history of intermittent claudication and either an ankle-brachial index &lt;0.9 or a significant peripheral artery stenosis ≥50% documented on imaging, or asymptomatic carotid artery stenosis≥50% / previous carotid revascularisation.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the mean body mass index (BMI) of participants in the COMPASS trial was lower than the expected mean BMI of New Zealand patients, and also noted that most patients participating in the trial were already well managed in terms of treatment and secondary prevention. The Committee noted that 90% of participants in the COMPASS trial had CAD, while only 27% had PAD.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that rivaroxaban in combination with aspirin was clinically and statistically superior to aspirin alone in reducing cardiovascular death, stroke, and myocardial infarction (hazard ratio (HR) 0.76; 95% CI 0.66 to 0.86; P&lt;0.001). The Committee also noted that rivaroxaban in combination with aspirin has a significant benefit in terms of stroke incidence compared to aspirin alone (HR 0.58; 95% CI 0.44 to 0.76; P&lt;0.001).</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was a higher incidence of major bleeding events with rivaroxaban in combination with aspirin, compared to aspirin alone (HR 1.70; 95% CI 1.40 to 2.05; P&lt;0.001), but noted that there was no difference between the treatment groups for intracranial bleeding. The Committee noted that the bleeding events were primarily manageable gastrointestinal events. The Committee noted that the net clinical benefit of rivaroxaban in combination with aspirin compared to aspirin alone still favoured the combination treatment regardless of the increase in bleeding events (HR 0.80; 95% CI 0.70 to 0.91; P&lt;0.001).</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a COMPASS sub-study in which the absolute benefit of rivaroxaban in combination with aspirin was demonstrated to be greater in the sub-set of patients with PAD as opposed to CAD alone (<a href=""https://pubmed.ncbi.nlm.nih.gov/29132880/"" target=""_blank"">Anand et al. Lancet. 2018;391:219-29</a>) and was sustained in patients with two or more vascular beds involved (<a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>), those with renal dysfunction (<a href=""https://pubmed.ncbi.nlm.nih.gov/31072566/"" target=""_blank"">Fox et al. J Am Coll Cardiol. 2019;73:2243-50</a>), heart failure (<a href=""https://pubmed.ncbi.nlm.nih.gov/31163978/"" target=""_blank"">Branch et al. Circulation. 2019;140:529-37</a>), those with diabetes mellitus (<a href=""https://pubmed.ncbi.nlm.nih.gov/32223318/"" target=""_blank"">Bhatt et al. Circulation. 2020;141:1841-54</a>), and regardless of BMI (<a href=""https://pubmed.ncbi.nlm.nih.gov/33538248/"" target=""_blank"">Guzik et al. J Am Coll Cardiol. 2021;77:511-25</a>).</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted that an additional study on the safety of proton pump inhibitors was conducted with patients from the COMPASS trial who received pantoprazole 40 mg once daily or placebo to determine if pantoprazole compared with placebo reduces the risk of upper gastrointestinal (GI) bleeding, ulceration, obstruction, or perforation in those participating in the trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a>). The Committee noted that addition of pantoprazole did not affect the occurrence of upper GI events in the rivaroxaban with aspirin arm but did significantly reduce upper GI events in the aspirin alone arm (HR 0.58; 95% CI 0.35 to 0.96).</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the COMPASS trial was well designed, and that the strength and quality of the evidence was high. The Committee considered that, as there are currently limited options for the treatment of PAD, rivaroxaban in combination with aspirin provides clinical benefit in terms of reducing ischaemia and amputation. The Committee considered that there were clinically beneficial endpoints.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the randomised, double-blind, placebo-controlled VOYAGER trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/32222135/"" target=""_blank"">Bonaca et al. N Engl J Med. 2020;382:1994-2004</a>) investigating the effects of rivaroxaban 2.5 mg twice daily in combination with aspirin once daily versus aspirin alone in those with PAD following arterial revascularisation. The Committee noted that the primary outcome was a composite of acute limb ischemia, major amputation, myocardial infarction, ischaemic stroke, and cardiovascular death. The Committee noted that the primary efficacy outcome occurred in 508 patients in the rivaroxaban group and in 584 in the placebo group; the Kaplan-Meier estimates of the incidence at 3 years were 17.3% and 19.9%, respectively (hazard ratio, 0.85, 95% CI, 0.76 to 0.96; P = 0.009). The Committee also noted that major bleeding occurred in 62 patients in the rivaroxaban group and in 44 patients in the placebo group (2.65% and 1.87%; hazard ratio, 1.43; 95% CI, 0.97 to 2.10; P = 0.07).</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the only currently funded therapy for the prevention of PAD and CAD is aspirin alone, and that there have been a number of trials investigating other agents such as aspirin in combination with clopidogrel or ticagrelor. The Committee noted that these other agents have demonstrated limited benefit after one year, and with limited to no mortality benefit (<a href=""https://pubmed.ncbi.nlm.nih.gov/30871353/"" target=""_blank"">Palmerini et al. Circ Cardiovasc Interv. 2019;12:e007541</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/25773268/"" target=""_blank"">Bonaca et al. N Engl J Med. 2015;372:1791-900</a>). The Committee also noted that warfarin has been shown to improve recurrent ischaemia outcomes but increases the risk of bleeding.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there have been various studies published with the aim to identify those at higher risk within the COMPASS trial cohort:</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a>: reported that rivaroxaban reduced cardiovascular event rates independently of the number of established CVD risk factors (poor control of blood pressure, cholesterol, smoking status), with similar relative risk reductions reported across groups of patients with differing numbers of risk factors. The Committee noted that the largest absolute benefit (in terms of &#39;numbers needed to treat&#39;) was reported in patients with the highest number of risk factors.</p><p class=""ql-indent-1"">1.19.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>: a COMPASS follow-on study conducted to identify subsets of patients in the COMPASS trial at higher risk of recurrent vascular events. The Committee noted that patients were stratified by risk using REACH (REduction of Atherothrombosis for Continued Health) atherothrombosis risk score and CART (Classification and Regression Tree) analysis, which reported that high-risk patients using the REACH score were those with two or more vascular beds affected, history of heart failure, or renal insufﬁciency, and by CART analysis were those with ≥2 vascular beds affected, history of heart failure, or diabetes. The Committee noted that for patients with multi-vessel disease, i.e. PAD with CAD, the absolute risk reduction for cardiovascular events was 6.02% (HR=0.64; 95% CI 0.51 to 0.81) versus 1.36% (HR=0.80; 95% CI 0.68 to 0.93) for patients with one vascular bed affected.</p><p class=""ql-indent-1"">1.19.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29132880/"" target=""_blank"">Anand et al. Lancet. 2018;391:219-29</a>: investigated cardiovascular death, myocardial infarction or stroke in participants with PAD; the primary peripheral artery disease outcome was major adverse limb events including major amputation. The Committee noted that the combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (5% vs 7%; HR 0.72; 95% CI 0.57 to 0.90; p=0.0047), and major adverse limb events including major amputation (1% vs 2%; HR 0.54; 95% CI 0.35 to 0.82; p=0.0037).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the COMPASS trial participants were not representative of the New Zealand Māori and Pacific patient population, as it included fewer smokers, fewer participants with chronic kidney disease, generally lower BMI patients, and lower diabetes incidence, and an over-representation of hypertension. The Committee considered, however, that any benefits from rivaroxaban in combination with aspirin would likely result in enhanced benefits for the Māori and Pacific patient population.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that using ankle-brachial index (ABI) as restriction criteria for access to rivaroxaban, if it were to be funded, may not be clinically appropriate, as it is only one component of the definition of PAD and is variably accessible across centres. The Committee also noted that treating those at a higher risk of adverse bleeding events comes down to individual clinical input and is regularly considered when initiating and managing patients on anticoagulant therapy. The Committee considered that there is a minimal need for haemostatic/reversal agents if rivaroxaban were to be funded for the requested indication, as higher doses of rivaroxaban have been funded in New Zealand for some time without the availability of a dedicated reversal agent.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that twice daily dosing is not as suitable as once daily dosing for most patients which may affect adherence to treatment over the long term.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the prevalence of PAD is 0.42%, equating to approximately 21,000 patients (<a href=""https://thehub.swa.govt.nz/resources/cardiovascular-disease-in-new-zealand-strategic-overview/"" target=""_blank"">National Health Committee, 2013</a>). The Committee considered that a restriction of rivaroxaban access based on identification of high-risk groups and a clear definition of underlying conditions, such as in <a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. (2019)</a> would limit patient numbers to those with the highest need.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the PBAC (Australia) guidelines for access to funded rivaroxaban for those with CAD and PAD, considered that the criteria were specific and detailed in their definitions of high-risk patient populations, and noted that ethnicity was included as a part of the Australian access criteria (for those with Aboriginal or Torres Straight Island descent). The Committee considered that this approach would also be appropriate in the New Zealand treatment context.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the patients who would benefit most from treatment with rivaroxaban include those with widespread disease (i.e. those with both PAD and CAD), and that those with the poorest risk control had the highest benefit in the COMPASS trial.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for rivaroxaban 2.5 mg if it were to be funded in New Zealand for the prevention of PAD with or without CAD. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. </span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0P2P0000078iOf&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002ZNDl"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for rivaroxaban for the first-line treatment of Peripheral Artery Disease (PAD) with or without Coronary Artery Disease (CAD).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for rivaroxaban for the first-line treatment of Peripheral Artery Disease (PAD) with or without Coronary Artery Disease (CAD).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cardiovascular Advisory Committee at meeting Wednesday 8 June 2022.', 'fs': 'Clinical advice received from Cardiovascular Advisory Committee at meeting Wednesday 8 June 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078iOfUAI'}, 'Id': 'a0P2P0000078iOfUAI', 'Event_Date__c': '2022-10-17', 'Event_Description__c': 'Clinical advice received from Cardiovascular Advisory Committee at meeting Wednesday 8 June 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Oct 2022', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that rivaroxaban for the treatment of PAD with or without CAD be listed with a <strong>medium</strong> <strong>priority</strong> within the context of treatment of cardiovascular disease, subject to the following Special Authority criteria:</p><p><strong style=""font-size: 9pt;"">INITIAL APPLICATION\xa0</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p><span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 8pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patients must have a confirmed diagnosis of peripheral artery disease (PAD) and must have one or more of the following high-risk factors:</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Concomitant coronary artery disease; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Confirmed diagnosis of PAD in two or more vascular beds; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diagnosed heart failure (left ventricular ejection fraction greater than or equal to 30% but less than 50%) ; or</span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diagnosed kidney disease classified by an eGFR 15-60ml/min; or </span></p><p class=""ql-indent-1""><span style=""font-size: 8pt;"">1.5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Diabetes Mellitus and at least one of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">age 60 years or more; or</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">concomitant microalbuminuria; or</span></p><p class=""ql-indent-2""><span style=""font-size: 8pt;"">1.5.3.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 8pt;"">Patient is of Māori or Pacific Island descent; and </span></p><p><span style=""font-size: 8pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patient must be prescribed rivaroxaban 2.5 mg twice daily in combination with 100 mg aspirin once daily; and</span></p><p><span style=""font-size: 8pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 8pt;"">Patient must not be on Dual Anti-Platelet therapy</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><strong style=""font-size: 9pt;"">RENEWAL:\xa0</strong></p><p><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment.\xa0</span></p><p><strong style=""font-size: 9pt;"">\xa0</strong></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee considered the high health need for the PAD with or without CAD patient population, and the lack of currently funded effective treatment options in making this recommendation.</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for rivaroxaban for the first-line treatment of Peripheral Artery Disease (PAD) with or without Coronary Artery Disease (CAD).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.</p>', 'Published_Discussion__c': '<h3><em>Māori</em> <em>impact</em></h3><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori experience peripheral artery disease (PAD) at a reported rate of 269 per 100,000 compared to the non-Māori population’s reported rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of arterial disease. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported.</p><p><em>Discussion</em></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a supplier application for the use of rivaroxaban 2.5mg for the first-line treatment PAD with or without coronary artery disease (CAD). The Committee noted that PTAC considered this application in <a href=""https://pharmac.govt.nz/assets/2021-02-18-PTAC-Record.pdf"" target=""_blank"">February 2021</a> where it was recommended for funding with a low priority for patients with PAD with or without CAD based on robust evidence of benefit, high health need for the requested population group, manageable bleeding risk with rivaroxaban, the need to fund a reversal agent if rivaroxaban were to be funded for this patient population, concern regarding the appropriate dosing for patients in the New Zealand context, and the Māori and Pacific population in New Zealand having a higher absolute risk of major adverse cardiac events (MACE) due to the presence of comorbidities such as obesity.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC recommended that advice be sought from the Cardiovascular Advisory Committee regarding identification of high-risk population groups, and appropriate Special Authority criteria.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that that PAD and CAD are clinical presentations of atherosclerosis, which is a progressive condition affecting the large and medium-sized arteries. The Committee noted that PAD and CAD develop in different vascular beds but can frequently coexist in patients with multi-vessel disease. The Committee also noted that the main risk factors for atherosclerosis include age, smoking, a family history of heart disease, unhealthy diet, and lack of physical activity. The Committee noted that PAD mainly affects the lower extremities and sometimes the carotid arteries, and can include asymptomatic and symptomatic disease, the latter including intermittent claudication, chronic limb ischemia, and acute limb ischemia, which can lead to gangrene and amputation. The Committee noted that the unstable plaques in atherosclerotic disease can rupture and trigger acute atherothrombotic events because of embolus formation, such as myocardial infarction, stroke, cardiovascular death, and acute limb ischemia.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PAD is broadly defined as a progressive stenosis or occlusion of any of the arteries except the coronary and intracranial arteries, and that patients with PAD are more than six times more likely to have a heart attack or stroke, and 13 times more likely to have lower limb amputation. The Committee noted that CAD is caused by atherosclerosis of the coronary arteries, which leads to a restriction of blood flow to the heart and can be categorised into acute coronary syndrome or chronic CAD. Acute coronary syndrome refers to a range of conditions associated with a sudden, reduced blood flow to the heart and includes unstable angina and acute myocardial infarction, and chronic CAD includes patients with stable angina and patients who have survived acute coronary syndrome events and have ‘restabilised’, although these patients remain at risk of recurrent major adverse cardiovascular events (MACE, which includes myocardial infarction, stroke and cardiovascular death).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee also noted that Māori experience PAD at a reported rate of 269 per 100,000 compared to the non-Māori population’s reported rate of 438 per 100,000. The Committee noted that Māori disproportionately experience death from stroke and have higher incidences of hospitalisation from cardiovascular disease, ischemic heart disease, and lower limb amputation as a result of PAD. The Committee considered that the burden of PAD in the Māori population is likely greatly underdiagnosed, and significantly higher than reported, as Māori patients experience a higher prevalence of CAD and exposure to its associated risk factors. The Committee considered that there is an increased carer and financial burden on the whānau and families of patients with complications from PAD/CAD and MACE, especially in cases like stroke where patients may not be able to work or perform day to day tasks.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that non-surgical treatment for peripheral vascular disease is limited to statins, aspirin, and smoking cessation, and that there is an unmet need for treatment options for this patient population. The Committee noted that for both PAD and CAD patient populations, there remains a high incidence of patients having recurrent events on currently available treatments.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the pivotal phase III COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial which gives the primary evidence for the health benefits of rivaroxaban for the prevention of cardiovascular events (<a href=""https://pubmed.ncbi.nlm.nih.gov/29132879/"" target=""_blank"">Connolly et al. Lancet. 2018;391:205-18</a>). The Committee noted that patients with stable CAD and/or PAD (N=27395) were randomised to receive rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily, rivaroxaban 5 mg alone twice daily, or aspirin 100 mg alone once daily. The Committee noted that participants in COMPASS were either 65 years of age or older or were under the age of 65 with documented atherosclerosis in two vascular beds or at least two additional risk factors. The Committee noted that the primary outcomes of COMPASS were composite incidence of cardiovascular related death or myocardial infarction, and that the primary safety outcome was incidence of major bleeding.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in the COMPASS trial, CAD was defined as previous myocardial infarction within the last 20 years, symptoms or history of stable or unstable angina with confirmed multivessel CAD &gt;50% in at least two coronary arteries (or in one coronary territory if at least one other territory has been revascularized), multivessel percutaneous coronary intervention, multivessel coronary artery bypass grafting (CABG). The Committee also noted that PAD was defined as previous peripheral vascular surgery or peripheral angioplasty intervention, previous amputation for arterial vascular disease, history of intermittent claudication and either an ankle-brachial index &lt;0.9 or a significant peripheral artery stenosis ≥50% documented on imaging, or asymptomatic carotid artery stenosis≥50% / previous carotid revascularisation.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the mean body mass index (BMI) of participants in the COMPASS trial was lower than the expected mean BMI of New Zealand patients, and also noted that most patients participating in the trial were already well managed in terms of treatment and secondary prevention. The Committee noted that 90% of participants in the COMPASS trial had CAD, while only 27% had PAD.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that rivaroxaban in combination with aspirin was clinically and statistically superior to aspirin alone in reducing cardiovascular death, stroke, and myocardial infarction (hazard ratio (HR) 0.76; 95% CI 0.66 to 0.86; P&lt;0.001). The Committee also noted that rivaroxaban in combination with aspirin has a significant benefit in terms of stroke incidence compared to aspirin alone (HR 0.58; 95% CI 0.44 to 0.76; P&lt;0.001).</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there was a higher incidence of major bleeding events with rivaroxaban in combination with aspirin, compared to aspirin alone (HR 1.70; 95% CI 1.40 to 2.05; P&lt;0.001), but noted that there was no difference between the treatment groups for intracranial bleeding. The Committee noted that the bleeding events were primarily manageable gastrointestinal events. The Committee noted that the net clinical benefit of rivaroxaban in combination with aspirin compared to aspirin alone still favoured the combination treatment regardless of the increase in bleeding events (HR 0.80; 95% CI 0.70 to 0.91; P&lt;0.001).</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted a COMPASS sub-study in which the absolute benefit of rivaroxaban in combination with aspirin was demonstrated to be greater in the sub-set of patients with PAD as opposed to CAD alone (<a href=""https://pubmed.ncbi.nlm.nih.gov/29132880/"" target=""_blank"">Anand et al. Lancet. 2018;391:219-29</a>) and was sustained in patients with two or more vascular beds involved (<a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>), those with renal dysfunction (<a href=""https://pubmed.ncbi.nlm.nih.gov/31072566/"" target=""_blank"">Fox et al. J Am Coll Cardiol. 2019;73:2243-50</a>), heart failure (<a href=""https://pubmed.ncbi.nlm.nih.gov/31163978/"" target=""_blank"">Branch et al. Circulation. 2019;140:529-37</a>), those with diabetes mellitus (<a href=""https://pubmed.ncbi.nlm.nih.gov/32223318/"" target=""_blank"">Bhatt et al. Circulation. 2020;141:1841-54</a>), and regardless of BMI (<a href=""https://pubmed.ncbi.nlm.nih.gov/33538248/"" target=""_blank"">Guzik et al. J Am Coll Cardiol. 2021;77:511-25</a>).</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee also noted that an additional study on the safety of proton pump inhibitors was conducted with patients from the COMPASS trial who received pantoprazole 40 mg once daily or placebo to determine if pantoprazole compared with placebo reduces the risk of upper gastrointestinal (GI) bleeding, ulceration, obstruction, or perforation in those participating in the trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a>). The Committee noted that addition of pantoprazole did not affect the occurrence of upper GI events in the rivaroxaban with aspirin arm but did significantly reduce upper GI events in the aspirin alone arm (HR 0.58; 95% CI 0.35 to 0.96).</p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the COMPASS trial was well designed, and that the strength and quality of the evidence was high. The Committee considered that, as there are currently limited options for the treatment of PAD, rivaroxaban in combination with aspirin provides clinical benefit in terms of reducing ischaemia and amputation. The Committee considered that there were clinically beneficial endpoints.</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the randomised, double-blind, placebo-controlled VOYAGER trial (<a href=""https://pubmed.ncbi.nlm.nih.gov/32222135/"" target=""_blank"">Bonaca et al. N Engl J Med. 2020;382:1994-2004</a>) investigating the effects of rivaroxaban 2.5 mg twice daily in combination with aspirin once daily versus aspirin alone in those with PAD following arterial revascularisation. The Committee noted that the primary outcome was a composite of acute limb ischemia, major amputation, myocardial infarction, ischaemic stroke, and cardiovascular death. The Committee noted that the primary efficacy outcome occurred in 508 patients in the rivaroxaban group and in 584 in the placebo group; the Kaplan-Meier estimates of the incidence at 3 years were 17.3% and 19.9%, respectively (hazard ratio, 0.85, 95% CI, 0.76 to 0.96; P = 0.009). The Committee also noted that major bleeding occurred in 62 patients in the rivaroxaban group and in 44 patients in the placebo group (2.65% and 1.87%; hazard ratio, 1.43; 95% CI, 0.97 to 2.10; P = 0.07).</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the only currently funded therapy for the prevention of PAD and CAD is aspirin alone, and that there have been a number of trials investigating other agents such as aspirin in combination with clopidogrel or ticagrelor. The Committee noted that these other agents have demonstrated limited benefit after one year, and with limited to no mortality benefit (<a href=""https://pubmed.ncbi.nlm.nih.gov/30871353/"" target=""_blank"">Palmerini et al. Circ Cardiovasc Interv. 2019;12:e007541</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/25773268/"" target=""_blank"">Bonaca et al. N Engl J Med. 2015;372:1791-900</a>). The Committee also noted that warfarin has been shown to improve recurrent ischaemia outcomes but increases the risk of bleeding.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that there have been various studies published with the aim to identify those at higher risk within the COMPASS trial cohort:</p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31615291/"" target=""_blank"">Vanassche et al. Eur J Prev Cardiol. 2020;27:296-307</a>: reported that rivaroxaban reduced cardiovascular event rates independently of the number of established CVD risk factors (poor control of blood pressure, cholesterol, smoking status), with similar relative risk reductions reported across groups of patients with differing numbers of risk factors. The Committee noted that the largest absolute benefit (in terms of &#39;numbers needed to treat&#39;) was reported in patients with the highest number of risk factors.</p><p class=""ql-indent-1"">1.19.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. J Am Coll Cardiol. 2019;73:3271-80</a>: a COMPASS follow-on study conducted to identify subsets of patients in the COMPASS trial at higher risk of recurrent vascular events. The Committee noted that patients were stratified by risk using REACH (REduction of Atherothrombosis for Continued Health) atherothrombosis risk score and CART (Classification and Regression Tree) analysis, which reported that high-risk patients using the REACH score were those with two or more vascular beds affected, history of heart failure, or renal insufﬁciency, and by CART analysis were those with ≥2 vascular beds affected, history of heart failure, or diabetes. The Committee noted that for patients with multi-vessel disease, i.e. PAD with CAD, the absolute risk reduction for cardiovascular events was 6.02% (HR=0.64; 95% CI 0.51 to 0.81) versus 1.36% (HR=0.80; 95% CI 0.68 to 0.93) for patients with one vascular bed affected.</p><p class=""ql-indent-1"">1.19.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29132880/"" target=""_blank"">Anand et al. Lancet. 2018;391:219-29</a>: investigated cardiovascular death, myocardial infarction or stroke in participants with PAD; the primary peripheral artery disease outcome was major adverse limb events including major amputation. The Committee noted that the combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (5% vs 7%; HR 0.72; 95% CI 0.57 to 0.90; p=0.0047), and major adverse limb events including major amputation (1% vs 2%; HR 0.54; 95% CI 0.35 to 0.82; p=0.0037).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the COMPASS trial participants were not representative of the New Zealand Māori and Pacific patient population, as it included fewer smokers, fewer participants with chronic kidney disease, generally lower BMI patients, and lower diabetes incidence, and an over-representation of hypertension. The Committee considered, however, that any benefits from rivaroxaban in combination with aspirin would likely result in enhanced benefits for the Māori and Pacific patient population.</p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that using ankle-brachial index (ABI) as restriction criteria for access to rivaroxaban, if it were to be funded, may not be clinically appropriate, as it is only one component of the definition of PAD and is variably accessible across centres. The Committee also noted that treating those at a higher risk of adverse bleeding events comes down to individual clinical input and is regularly considered when initiating and managing patients on anticoagulant therapy. The Committee considered that there is a minimal need for haemostatic/reversal agents if rivaroxaban were to be funded for the requested indication, as higher doses of rivaroxaban have been funded in New Zealand for some time without the availability of a dedicated reversal agent.</p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that twice daily dosing is not as suitable as once daily dosing for most patients which may affect adherence to treatment over the long term.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the prevalence of PAD is 0.42%, equating to approximately 21,000 patients (<a href=""https://thehub.swa.govt.nz/resources/cardiovascular-disease-in-new-zealand-strategic-overview/"" target=""_blank"">National Health Committee, 2013</a>). The Committee considered that a restriction of rivaroxaban access based on identification of high-risk groups and a clear definition of underlying conditions, such as in <a href=""https://pubmed.ncbi.nlm.nih.gov/31248548/"" target=""_blank"">Anand et al. (2019)</a> would limit patient numbers to those with the highest need.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted the PBAC (Australia) guidelines for access to funded rivaroxaban for those with CAD and PAD, considered that the criteria were specific and detailed in their definitions of high-risk patient populations, and noted that ethnicity was included as a part of the Australian access criteria (for those with Aboriginal or Torres Straight Island descent). The Committee considered that this approach would also be appropriate in the New Zealand treatment context.</p><p><span style=""color: black;"">1.25.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that the patients who would benefit most from treatment with rivaroxaban include those with widespread disease (i.e. those with both PAD and CAD), and that those with the poorest risk control had the highest benefit in the COMPASS trial.</p><p><span style=""color: black;"">1.26.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for rivaroxaban 2.5 mg if it were to be funded in New Zealand for the prevention of PAD with or without CAD. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff. </span></p><p><span style=""color: black;"">\ufeff</span><img src=""/apptracker/servlet/rtaImage?eid=a0P2P0000078iOf&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002ZNDl"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000EDAbQAO'}, 'change': None}]",Oct 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2022', 'fs': 'Nov 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000078iOgUAI'}, 'Id': 'a0P2P0000078iOgUAI', 'Event_Date__c': '2022-11-30', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2022', 'Status_History__c': 'a132P000000EDa2QAG'}, 'change': None}]",Nov 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
